Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 3/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | BUB1 | O43683 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.41 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641665 | 0.90 | FGFR2 (0.64) | FGFR2FLT3BRAFFYNBUB1 | |
| SCHEMBL1641600 | 0.79 | CDK2 (0.53) | SYKMAPK1PIP4K2APIP4K2BPRKCQ | |
| SCHEMBL8788688 | 0.77 | SYK (0.50) | FGFR2FLT3BUB1SYKPRKCQ | |
| SCHEMBL1642602 | 0.77 | FYN (0.53) | FGFR2FLT3BRAFFYNSYK | |
| SCHEMBL22803683 | 0.74 | BTK (0.42) | SYKKDRATRPRKCQAPP | |
| SCHEMBL30302570 | 0.74 | BTK (0.42) | SYKKDRATRPRKCQAPP | |
| SCHEMBL1640843 | 0.73 | BRAF (0.57) | FGFR2FLT3BRAFFYNSYK | |
| SCHEMBL1122025 | 0.72 | KDR (0.70) | FGFR2BRAFKDRCDK1 | |
| SCHEMBL12129007 | 0.72 | SYK (0.55) | SYKMAPK1 | |
| SCHEMBL12128995 | 0.70 | APP (0.67) | SYKAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | claimed |
| CN-101970418-B | Pyrazine derivative and its uses as protein kinase inhibitor | AKINION PHARMACEUTICALS AB | 2013-07-03 | — | — | CN | claimed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | claimed |
| CN-101970418-A | Novel compounds, use and preparation thereof | AKINION PHARMACEUTICALS AB | 2011-02-09 | — | — | CN | claimed |
| EP-2252597-B1 | PYRAZINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | AKINION PHARMACEUTICALS AB (SE) | 2014-03-19 | — | — | EP | disclosed |
| EP-2671876-A2 | Pyrazine derivatives and their use as protein kinase inhbitors | Akinion Pharmaceuticals AB (SE) | 2013-12-11 | — | — | EP | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| CN-101970418-B | Pyrazine derivative and its uses as protein kinase inhibitor | AKINION PHARMACEUTICALS AB | 2013-07-03 | — | — | CN | disclosed |
| US-8436171-B2 | Amino substituted pyrazines as inhibitors or protein kinases | AKINION PHARMACEUTICALS AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-8436171-B2 | Amino substituted pyrazines as inhibitors or protein kinases | AKINION PHARMACEUTICALS AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| CN-101970418-A | Novel compounds, use and preparation thereof | AKINION PHARMACEUTICALS AB | 2011-02-09 | — | — | CN | disclosed |
| EP-2252597-A2 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | Akinion Pharmaceuticals AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009095399-A2 | PYRAZINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHBITORS | AKINION PHARMACEUTICALS AB (SE) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095399-A2 | PYRAZINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHBITORS | AKINION PHARMACEUTICALS AB (SE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | FGFR2 329/4885FLT3 1/4885BRAF 12/4885 |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | FGFR2 329/4885FLT3 1/4885BRAF 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.